|
Name |
Euphorbadienol
|
Molecular Formula | C31H52O | |
IUPAC Name* |
(3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-[(2S)-6-methyl-5-methylideneheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
|
SMILES |
C[C@@H](CCC(=C)C(C)C)[C@@H]1CC[C@]2([C@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
|
InChI |
InChI=1S/C31H52O/c1-20(2)21(3)10-11-22(4)23-14-18-31(9)25-12-13-26-28(5,6)27(32)16-17-29(26,7)24(25)15-19-30(23,31)8/h20,22-23,26-27,32H,3,10-19H2,1-2,4-9H3/t22-,23-,26-,27-,29+,30-,31+/m0/s1
|
|
InChIKey |
XJLZCPIILZRCPS-CKCUNPICSA-N
|
|
Synonyms |
Euphorbadienol; Euphorbol; 566-14-3; alpha-Euphorbol; (3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-((S)-6-methyl-5-methyleneheptan-2-yl)-2,3,4,5,6,7,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; gamma-Euphorbol; CHEMBL518556; SCHEMBL7194852; HY-125648; CS-0092605; Lanost-8-en-3-ol, 24-methylene-, (3beta,13alpha,14beta,17alpha,20S)-; (3S,5R,10S,13S,14S,17S)-4,4,10,13,14-pentamethyl-17-[(2S)-6-methyl-5-methylideneheptan-2-yl]-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
|
|
CAS | 566-14-3 | |
PubChem CID | 10863111 | |
ChEMBL ID | CHEMBL518556 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 440.7 | ALogp: | 9.4 |
HBD: | 1 | HBA: | 1 |
Rotatable Bonds: | 5 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 20.2 | Aromatic Rings: | 4 |
Heavy Atoms: | 32 | QED Weighted: | 0.383 |
Caco-2 Permeability: | -4.947 | MDCK Permeability: | 0.00001190 |
Pgp-inhibitor: | 0.937 | Pgp-substrate: | 0.003 |
Human Intestinal Absorption (HIA): | 0.023 | 20% Bioavailability (F20%): | 0.998 |
30% Bioavailability (F30%): | 0.878 |
Blood-Brain-Barrier Penetration (BBB): | 0.129 | Plasma Protein Binding (PPB): | 93.86% |
Volume Distribution (VD): | 1.288 | Fu: | 1.74% |
CYP1A2-inhibitor: | 0.057 | CYP1A2-substrate: | 0.397 |
CYP2C19-inhibitor: | 0.086 | CYP2C19-substrate: | 0.967 |
CYP2C9-inhibitor: | 0.255 | CYP2C9-substrate: | 0.103 |
CYP2D6-inhibitor: | 0.121 | CYP2D6-substrate: | 0.06 |
CYP3A4-inhibitor: | 0.855 | CYP3A4-substrate: | 0.925 |
Clearance (CL): | 14.405 | Half-life (T1/2): | 0.008 |
hERG Blockers: | 0.498 | Human Hepatotoxicity (H-HT): | 0.197 |
Drug-inuced Liver Injury (DILI): | 0.173 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.681 | Maximum Recommended Daily Dose: | 0.914 |
Skin Sensitization: | 0.263 | Carcinogencity: | 0.365 |
Eye Corrosion: | 0.022 | Eye Irritation: | 0.042 |
Respiratory Toxicity: | 0.938 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002119 | 0.618 | D0Y7LD | 0.331 | ||||
ENC002718 | 0.474 | D0K5WS | 0.312 | ||||
ENC005968 | 0.419 | D0Z1XD | 0.289 | ||||
ENC001603 | 0.419 | D0G3SH | 0.283 | ||||
ENC003486 | 0.415 | D03ZTE | 0.283 | ||||
ENC001119 | 0.415 | D02ZGI | 0.282 | ||||
ENC006068 | 0.415 | D0L2LS | 0.280 | ||||
ENC006069 | 0.411 | D02VPX | 0.277 | ||||
ENC005630 | 0.405 | D0M4WA | 0.273 | ||||
ENC003755 | 0.391 | D08SVH | 0.273 |